Literature DB >> 7881728

Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart.

M G Peter1, A P Davenport.   

Abstract

1. Endothelin-1 binds with high affinity to heart where it acts as a potent positive inotropic agent. Our aim was to characterize the labelled and unlabelled ETA-selective antagonist PD151242 in heart tissues derived from man, rat and pigs by use of radioligand binding techniques. 2. Binding of [125I]-PD151242 to sections of human left ventricle was time-dependent and reached equilibrium after 120 min at 23 degrees C with an association rate constant of 0.0235 min-1 nM-1. The binding was reversible at 23 degrees C with a dissociation rate constant of 0.00144 min-1. 3. Saturation binding assays with [125I]-PD151242 revealed a single population of high affinity ET receptors in human left ventricle (KD = 1.07 +/- 0.08 nM; Bmax = 29.8 +/- 4.2 fmol mg-1 protein), porcine left ventricle (KD = 1.92 +/- 0.27 nM; Bmax = 493 +/- 248 fmol mg-1 protein), and rat heart (KD = 0.64 +/- 0.08 nM; Bmax = 82.34.7 fmol mg-1 protein). 4. Unlabelled PD151242 competed with specific [125I]-ET-1 binding to human left ventricle tissue in a biphasic manner with high affinity binding to the ETA-site (KD = 7.21 +/- 2.83 nM) and lower affinity for the ETB-subtype (KD = 104 +/- 23 microM), indicating a greater than 10000 fold selectivity to the high affinity site. 5. The ETA-selective ligand FR139317 competed for [125I]-PD151242 binding in human left ventricle with nanomolar affinity (KD = 0.37 +/- 0.10 nM), whereas the ETB-selective compound, BQ3020, competed with only micromolar affinity (KD = 1.5 +/- 0.26 microM). 6. The novel ETA-selective radioligand [125I]-PD151242 binds with high affinity to human, rat and porcine heart. In human tissue, binding was shown to be reversible and highly selective for the ETA-subtype making [1251]-PD151242 a useful selective radioligand for further characterization of the ETA-receptor in human tissue.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7881728      PMCID: PMC1510233          DOI: 10.1111/j.1476-5381.1995.tb13226.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  A novel subtype of endothelin receptors.

Authors:  M Sokolovsky; I Ambar; R Galron
Journal:  J Biol Chem       Date:  1992-10-15       Impact factor: 5.157

2.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.

Authors:  M Ihara; K Noguchi; T Saeki; T Fukuroda; S Tsuchida; S Kimura; T Fukami; K Ishikawa; M Nishikibe; M Yano
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart.

Authors:  P Molenaar; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

4.  Localization of endothelin binding sites and endothelin-like immunoreactivity in human fetal heart.

Authors:  J Wharton; R A Rutherford; L Gordon; G Moscoso; I Schiemberg; J A Gaer; K M Taylor; J M Polak
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 5.  Tissue specificity of the endothelin-induced responses.

Authors:  T Masaki
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

6.  Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney.

Authors:  A P Davenport; A J Morton; M J Brown
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

7.  Multiple subtypes of endothelin receptors in human and porcine tissues: characterization by ligand binding, affinity labeling, and regional distribution.

Authors:  R Takayanagi; K Ohnaka; C Takasaki; M Ohashi; H Nawata
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

8.  Calculating receptor number from binding experiments using same compound as radioligand and competitor.

Authors:  A DeBlasi; K O'Reilly; H J Motulsky
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

9.  Increased plasma level of endothelin-1-like immunoreactivity during coronary spasm in patients with coronary spastic angina.

Authors:  K Matsuyama; H Yasue; K Okumura; Y Saito; K Nakao; G Shirakami; H Imura
Journal:  Am J Cardiol       Date:  1991-10-15       Impact factor: 2.778

10.  Contribution of endogenous endothelin to the extension of myocardial infarct size in rats.

Authors:  T Watanabe; N Suzuki; N Shimamoto; M Fujino; A Imada
Journal:  Circ Res       Date:  1991-08       Impact factor: 17.367

View more
  8 in total

1.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

2.  Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.

Authors:  O Feron; S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

3.  Molecular mechanisms of benzodiazepine-induced down-regulation of GABAA receptor alpha 1 subunit protein in rat cerebellar granule cells.

Authors:  M J Brown; D R Bristow
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

4.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

5.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

Authors:  A P Davenport; G O'Reilly; R E Kuc
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

Review 7.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

8.  Endothelin ETA receptor expression in human cerebrovascular smooth muscle cells.

Authors:  J C Yu; J D Pickard; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.